CompletedPhase 1

Study Evaluating the Effect of Lecozotan SR on the QTc Interval

A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Asset

Lecozotan

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-55

Primary endpoint

•Effect of drug administration on QTc interval

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID3098B1-133

NCT IDNCT00499642

Timeline

Milestones

Study start2007-06 (month precision)

Study first posted2007-07-11estimated

Study completion2007-08actual (month precision)

Last update posted2007-12-28estimated

Assets

Drug assets

Lecozotan

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Women and men aged 18 to 55 years inclusive.

•Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG)

Exclusion criteria

•History of any clinically important drug allergy.

•Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

To assess the effect of drug administration on QTc interval.

ratio, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.